Business Wire

MI-EATON

13.9.2022 12:31:36 CEST | Business Wire | Press release

Share
Eaton’s Royal Power Solutions to display commercial vehicle terminals and connectors portfolio at IAA Transportation show

Power management company Eaton announced Royal Power Solutions (RPS), a leading provider of high-precision electrical connectivity components that it acquired earlier this year, is now providing its industry-leading components to commercial vehicle manufacturers. RPS components will be displayed Sept. 20-25 in Eaton’s exhibit at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005003/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s Royal Power Solutions is an industry-leading provider of critical high-precision power- and signal-distribution terminals and connectors. (Photo: Business Wire)

RPS, established in 1938, is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors. Eaton is utilizing RPS products in its eMobility business and expanding its global market opportunities, including in Europe, Middle East and Africa (EMEA).

“Eaton’s global footprint and diversification have broadened Royal Power Solutions’ reach and ability to grow in EMEA,” said Tom Ross, president, Eaton’s Royal Power Solutions. “The market for terminals and connectors in EMEA continues to expand in parallel with electrification solutions, which are being increasingly adopted by our commercial vehicle customers.”

Electrified commercial vehicles need more power than traditional passenger vehicles to operate varying systems. RPS, recognized for its numerous industry-leading electrical solutions, provides terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial vehicles.

High Power Lock Box connectors provide protection, superior performance

Eaton’s RPS specialized High Power Lock Box (HPLB) power connectors are ideal for current electrified commercial vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer superior performance, cost savings and reduced manufacturing complexity. They also provide efficiency and reliability and are strong enough to withstand high-pressure water spray.

HPLB terminals are a “plug-in” solution with a smaller footprint, resulting in less weight and a reduced profile compared to traditional terminals. Eaton’s RPS uses a progressive stamping process to manufacture the HPLB profiles rather than the more costly complex billet machining, stamping and forming process that competitive products require.

Unlike traditional male-to-female terminal connections, Eaton’s RPS HPLB terminals use a unique inverted contact system that provides improved contact force as the temperature increases, creating a stronger connection.

RPS busbars feature low profile, flexibility to meet design requirements

Another RPS component now available to Eaton’s EMEA commercial vehicle customers is RigiFlexTM busbars, manufactured in copper or aluminum based on customer requirements. With a unique, simple, single-piece flow manufacturing process, Eaton can scale volume to meet any customer specification.

The RigiFlex busbar is rigid in some areas but flexible in sections that require elevation changes within the system design. This flexibility also works well across the battery pack in areas that need tolerance for expansion and contraction due to fluctuating temperatures during charging and discharging cycles.

Eaton’s RPS busbars have a low profile to enable space-efficient design without heat sinks, which leads to weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors, which fulfills size and design requirements. Eaton’s RPS can leverage an automated assembly process to provide superior safety, reduce production time and offer maximum cost savings with little wasted material and nearly zero development time for production products.

Eyelet terminals sealed, protected against galvanic corrosion

Eaton’s eyelet terminals, another RPS solution, are crafted with sophisticated engineering and produced in our state-of-the-art stamping facilities. Sourcing eyelet terminals from RPS provides numerous benefits, including the ability to produce billions of parts annually for the single sourcing of large programs.

Traditionally, eyelet terminals in commercial vehicle electrical components are not sealed, exposing them to road spray and salt that accelerate galvanic corrosion. Eaton’s eyelet terminals from RPS provide fully sealed connectors that are resistant to severe vibration and deliver a component service life exceeding customer requirements.

“RPS has decades of design, manufacturing and stamping experience that is being leveraged in the introduction of new energy-transfer technologies,” Ross said. “Many of the components RPS supplies, including eyelets, busbars, High Power Lock Box terminals and full-service connectors, are essential in today’s commercial vehicles.”

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye